Amylyx Pharmaceuticals (AMLX) Receivables - Net (2022 - 2025)

Amylyx Pharmaceuticals' Receivables - Net history runs 4 years deep, the most recent figure standing at $88000.0 for Q4 2025.

• In Q4 2025, Receivables - Net fell 80.31% year-over-year to $88000.0; the TTM figure through Dec 2025 stood at $88000.0 (down 80.31% YoY), while the FY2025 annual figure was $88000.0, down 80.31% from the prior year.
• Receivables - Net was $88000.0 for Q4 2025 at Amylyx Pharmaceuticals, down from $132000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $40.0 million in Q4 2023 to a low of $88000.0 in Q4 2025.
• Historically, Receivables - Net has averaged $11.7 million across 4 years, with a median of $2.9 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net soared 21325.55% in 2023, then plunged 98.88% in 2024.
• A 4-year view of Receivables - Net shows it stood at $15.3 million in 2022, then surged by 161.66% to $40.0 million in 2023, then slumped by 98.88% to $447000.0 in 2024, then plunged by 80.31% to $88000.0 in 2025.
• The last three Receivables - Net figures came in at $88000.0 (Q4 2025), $132000.0 (Q3 2025), and $103000.0 (Q2 2025), per Business Quant data.